Meet MinimaBio. Drug discovery is a lengthy, expensive process, with many candidates failing at the clinical trial stage due to toxicity or low efficacy, typically a failure of drug specificity. The TeamMinimaBio was founded by Natalie Tatum and Mathew Martin. Together they have over two decades’ experience in enabling targets and prosecuting them through to pre-clinical development. Their deep and closely aligned interactions with pharmaceutical industry alliance partners and patient benefit charities gave them confidence that their technology would make a significant impact in the drug discovery sector, due to both its initial low-risk/high-return strategy, but also the ability to plug-in and run in parallel with existing drug discovery pipeline make-test cycles. ProblemDrug discovery is a lengthy, expensive process, with many candidates failing at the clinical trial stage due to toxicity or low efficacy, typically a failure of drug specificity.SolutionMinimaBio offer a route to novel targeting paradigms, which can bring challenging targets back into the drug development pipeline. With our bespoke ML-led approach, MinimaBio can open up new avenues for drug discovery and accelerate programmes towards novel NCEs.ContactMinimaBio website This article was published on 2025-10-28
